China Biologic Products Holdings, Inc. (CBPO) Company Bio
China Biologic Products engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in China. The company is based in Beijing, the China.
CBPO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for CBPO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that China Biologic Products Holdings Inc ranked in the 60th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of China Biologic Products Holdings Inc, consider:
Interest coverage, a measure of earnings relative to interest payments, is 312.17 -- which is good for besting 97.39% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than just 0% of the free cash flow producing stocks we're observing.
CBPO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 61.19% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of China Biologic Products Holdings Inc? See DRRX, PBH, UTHR, NHC, and RSCF.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan") to China Biologic, which attempts to terminate the cooperation between China Biologic and Xinjiang Deyuan, and urges Xinjiang Deyuan to cure its breaches and continue to perform its obligations under its cooperation agreement with China Biologic. In addition, the Company announced that, through the lawsuits it previously filed against Xinjiang Deyuan, the Company is seeking monetary claims totaling over RMB460 million and has obtained judicial freezing of certain s...
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
An earnings release is available on the Company's website. Today, you will hear from China Biologic's Chairman and CEO, Mr. Joseph Chow, who will start off the call with a review of the Company's basic operating results and report recent developments for the Company. China Biologic's CFO, Mr. Ming Yang, will be available during the Q&A session following the prepared remarks.